Adenovirus-based prime-boost immunization for rapid vaccination against anthrax

Molecular Therapy

Volumn 15, Issue 1, 2007, Pages 203-210

  McConnell, Michael J ^a   Hanna, Philip C ^a   Imperiale, Michael J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTHRAX VACCINE; BACTERIAL ANTIGEN; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL SPORE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOUSE; NONHUMAN; PROTEIN DOMAIN; TREATMENT DURATION; VACCINATION; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CELL LINE; FEMALE; HUMANS; IMMUNIZATION; MICE; SPLEEN; TIME FACTORS;

ADENOVIRIDAE; BACILLUS ANTHRACIS; BACTERIA (MICROORGANISMS);

EID: 33845977765     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300034     Document Type: Article

References (37)

1. Dixon, TC, Meselson, M, Guillemin, J and Hanna, PC (1999). Anthrax. N Engl J Med 341: 815-826.
2. Moayeri, M and Leppla, SH (2004). The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol 7: 19-24.
3. Pitt, ML et al. (2001). In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19: 4768-4773.
4. Reuveny, S et al. (2001). Search for correlates of protective immunity conferred by anthrax vaccine. Infect Immun 69: 2888-2893.
5. Ivins, BE and Welkos, SL. (1988). Recent advances in the development of an improved, human anthrax vaccine. Eur J Epidemiol 4: 12-19.
6. Xie, H et al. (2005). CpG oligodeoxynucleotides adsorbed onto polylactide-coglycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine. Infect Immun 73: 828-833.
7. Sever, JL et al. (2004). Safety of anthrax vaccine: An expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Pharmacoepidemiol Drug Saf 13: 825-840.
8. Geier, DA and Geier, MR. (2002). Anthrax vaccination and joint related adverse reactions in light of biological warfare scenarios. Clin Exp Rheumatol 20: 217-220.
9. Pittman, PR, Gibbs, PH, Cannon, TL and Friedlander, AM. (2001). Anthrax vaccine: Short-term safety experience in humans. Vaccine 20: 972-978.
10. Woodland, DL. (2004). Jump-starting the immune system: Prime-boosting comes of age. Trends Immunol 25: 98-104.
11. Shiver, JW et al. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
12. Wu, L, Kong, WP and Nabel, GJ. (2005). Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J Virol 79: 8024-8031.
13. Santra, S et al. (2005). Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79: 6516-6522.
14. Mennuni, C et al. (2005). Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int J Cancer 117: 444-455.
15. Sullivan, NJ et al. (2003). Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424: 681-684.
16. Tritel, M et al. (2003). Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol 171: 2538-2547.
17. Rollier, C et al. (2005). Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J Infect Dis 192: 920-929.
18. Perkins, SD, O'Brien, LM and Phillpotts, RJ. (2006). Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination. Vaccine 24: 3440-3445.
19. Flick-Smith, HC et al. (2002). A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect Immun 70: 1653-1656.
20. McConnell, MJ, Hanna, PC and Imperiale, MJ. (2006). Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infect Immun 74: 1009-1015.
21. DeKruyff, RH, Rizzo, LV and Umetsu, DT. (1993). Induction of immunoglobulin synthesis by CD4+ T cell clones. Semin Immunol 5: 421-430.
22. Friedlander, AM (1986). Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J Biol Chem 261: 7123-7126.
23. Welkos, SL, Keener, TJ and Gibbs, PH (1986). Differences in susceptibility of inbred mice to Bacillus anthracis. Infect Immun 51: 795-800.
24. Zoltick, PW, Chirmule, N, Schnell, MA, Gao, GP, Hughes, JV and Wilson, JM. (2001). Biology of E1-deleted adenovirus vectors in nonhuman primate muscle. J Virol 75: 5222-5229.
25. Vietri, NJ et al. (2006). Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci USA 103: 7813-7816.
26. Tan, Y, Hackett, NR, Boyer, JL and Crystal, RG. (2003). Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum Gene Ther 14: 1673-1682.
27. Hashimoto, M, Boyer, JL, Hackett, NR, Wilson, JM and Crystal, RG. (2005). Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun 73: 6885-6891.
28. Aulinger, BA, Roehrl, MH, Mekalanos, JJ, Collier, RJ and Wang, JY. (2005). Combining anthrax vaccine and therapy: A dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines. Infect Immun 73: 3408-3414.
29. Petosa, C, Collier, RJ, Klimpel, KR, Leppla, SH and Liddington, RC. (1997). Crystal structure of the anthrax toxin protective antigen. Nature 385: 833-838.
30. Firoved, AM et al. (2005). Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol 167: 1309-1320.
31. Zeng, M, Xu, Q, Hesek, ED and Pichichero, ME. (2006). N-fragment of edema factor as a candidate antigen for immunization against anthrax. Vaccine 24: 662-670.
32. Welkos, S, Little, S, Friedlander, A, Fritz, D and Fellows, P. (2001). The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147: 1677-1685.
33. Top Jr, FH, Dudding, BA, Russell, PK and Buescher, EL. (1971). Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol 94: 142-146.
34. Buller, RE et al. (2002). A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 9: 553-566.
35. Sterman, DH et al. (2005). Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 11: 7444-7453.
36. Zhang, W and Imperiale, MJ. (2003). Requirement of the adenovirus IVa2 protein for virus assembly. J Virol 77: 3586-3594.
37. McConnell, MJ, Danthinne, X and Imperiale, MJ. (2006). Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol 80: 5361-5370.